AmeriServ Wealth Advisors’s AstraZeneca AZN Stock Holding History

AmeriServ Wealth Advisors’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q1	–	Sell	-7,890	Closed	-$535K	–	28
2015 Q4	$535K	Buy	7,890 +50	+0.6%	+$3.28K	1.27%	23
2015 Q3	$499K	Sell	7,840 -1,521	-16%	-$100K	0.95%	25
2015 Q2	$596K	Sell	9,361 -1,532	-14%	-$105K	0.69%	32
2015 Q1	$745K	Sell	10,893 -75	-0.7%	-$5.21K	0.86%	30
2014 Q4	$772K	Buy	10,968 +185	+2%	+$13.2K	0.75%	27
2014 Q3	$770K	Buy	+10,783	New	+$789K	1.33%	19

Other funds holding AZN

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

EIP

Epoch Investment Partners New York $16.5B AUM 24.3% 1-Year Est. Return

Cambiar Investors Denver, Colorado $2.16B AUM 16.24% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

SCCM

Schafer Cullen Capital Management New York $491M AUM 41.48% 1-Year Est. Return

Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return

AmeriServ Wealth Advisors's AZN Position: Q1 2016 in Review

AmeriServ Wealth Advisors sold out of AstraZeneca (AZN) in Q1 2016, closing a stake of 7,890 shares — an estimated $535K sold.

AmeriServ Wealth Advisors first reported a position in AZN in Q3 2014 and held it in 6 quarters. The position peaked at $772K in Q4 2014. 389 funds tracked by Wall St. Rank hold AZN as of Q1 2016.

AmeriServ Wealth Advisors reported no remaining AstraZeneca position as of Q1 2016 after selling out during the quarter.
AmeriServ Wealth Advisors sold 7,890 AstraZeneca shares in Q1 2016, an estimated $535K.
AmeriServ Wealth Advisors first reported a position in AstraZeneca in Q3 2014 and held it in 6 quarters.
AmeriServ Wealth Advisors's AstraZeneca position peaked at $772K in Q4 2014.
389 funds tracked by Wall St. Rank held AstraZeneca as of Q1 2016.

Based on AmeriServ Wealth Advisors's 13F filing for Q1 2016, filed 13 May 2016.